Organon Prep Session "Welcome to Organon, where health matters.

1
Organon Prep Session"Welcome to Organon, where
health matters.

• Rutgers Business School
• December 6, 2007
• Prepared by
• Loubna Erraji
• Elizabeth Moore
• Sean Ryan
• Advisor Elena Aravanitis

2
2007 Organon BiosciencesAcquired by
Schering-Plough

• Announced 3/12/07
• Completed 11/19/07
• about 14.4 B (11 billion)

3
Our Mission

• Organon creates and markets prescription
  medicines that improve the health and quality of
  human life.
• Our Vision?
• Through a combination of independent growth and
  business partnerships, Organon strives to become
  or remain one of the leading pharmaceutical
  companies in each of its core therapeutic fields
  gynecology, fertility, neuroscience and
  anesthesia.

4
Our Values

• Trust. Trust is the basis for all our
  relationships. It is developed through honesty,
  openness and commitment. Organon trusts that each
  employee performs for the companys best
  interests.
• Respect. Organon takes people seriously, listens
  to their ideas and opinions with an open mind and
  encourages them to participate in the
  decision-making process.
• Integrity. Organon employees are transparent in
  their actions and intentions, avoiding politics
  and completing what they have set out to do.
• Entrepreneurial Spirit. Creative and flexible,
  Organon explores opportunities to develop new
  products that exceed the needs and expectations
  of our customers. Organon stimulates creativity
  in the workplace by asking Why not to novel ideas
  instead of Yes, but . . .
• Quality. Organon creates and markets products of
  the highest quality independent of time, place
  and circumstances. The quality of our products
  and our respect for the environment are foremost
  in the decisions we make.Excellence. Organon
  employees strive for excellence in everything
  they do, continually improving performance and
  measuring results.

5
Company History

• 1921 First product, insulin, discovered.
• 1923 Founded in Oss, Netherlands
• 1969 Merged with AKU, a fibers company, to
  become AKZO. Organon is now a business unit of
  AKZO (later Akzo Nobel).
• 2002 - Established a new international office in
  New Jersey.

6
Recent Developments

• 2003 Akzo Nobel and Pfizer collaborate for
  Asenapine to treat schizophrenia and bipolar
  disorders.
• 2005 Opened Organon Research Center USA in
  Cambridge, Massachusetts
• 2006 Collaboration with KineMed to discover new
  applications.
• 2006 Collaboration with Irish National Institute
  for Bioprocessing Research and Training (NIBRT)
  for glycosylation.
• 2007 Collaboration with HUYA Biosciences
  International (HUYA) to find new compounds.
• 2007 Collaboration with Academic Medical center
  (AMC) for rheumatoid arthritis therapy.

7
Schering-Plough mostly consumer products
8
Schering-Plough has some Rx products, but not
many

• Pegintron hepatitis C
• Nasonex allergy nasal spray
• Remicade immune-medicated anti-inflammatory
• Vytorin cholesterol-lowering (JV with Merck)
• Zetia cholesterol-lowering (JV with Merck)

9
Reasons to Acquire Organon

• Five Organon Phase III compounds
• Diversification
• a) Womens health (Organon)
• b) CNS compounds (Organon)
• c) Animal health products (Intervet)
• Economies of scale/scope

10
Organon Annual Sales

• 1990 Euro 608 million
• 1997 Euro 1,145 million
• 1998 Euro 1,308 million
• 1999 Euro 1,618 million
• 2000 Euro 1,977 million
• 2001 Euro 2,420 million
• 2002 Euro 2,593 million
• 2003 Euro 2,273 million
• 2004 Euro 1,975 million
• 2005 Euro 2,425 million
• 2006 Euro 2,611 million

11
Schering-Plough Stock

• (NYSE) SGP
• Closed at 31.19 on December 5, 2007
• 52 Week Range 22.30 - 31.81

12
Employment and Workforce

• 13,700 employees spread across the following
  areas
• Medical / Pharmaceutical Information 3,665
• Marketing / Services / Distribution 1,517
• Manufacturing 4,020
• Research Development 2,444
• Other 2,061

13
News and Events

• Wednesday, December 5, 2007
• Schering-Plough was honored by Scrip World
  Pharmaceutical News last night with three top
  pharmaceutical industry awards
• Large Pharma Company of the Year
• Management Team of the Year
• Executive of the Year for Fred Hassan,
• Schering-Plough chairman and CEO

14
News and Events

• Monday, November 26, 2007
• Schering-Plough Corporation today announced that
  the U.S. Food and Drug Administration (FDA)
  recently accepted the filing for review of the
  New Drug Application (NDA) for asenapine, a
  fast-dissolving, sublingual tablet.
  Schering-Plough is seeking marketing approval
  from the FDA for the treatment of schizophrenia
  and acute mania or mixed episodes associated with
  Bipolar I Disorder. In accepting the NDA, the FDA
  indicated that asenapine will receive a standard
  review.

15
News and Events

• Tuesday, October 02, 2007 (Osaka, Japan)
• Nippon Organon K.K. today announced the launch
  of rocuronium bromide, its neuromuscular blocking
  agent (NMBA) for use during general anesthesia,
  under the brand names Eslax 25mg/2.5ml and
  Eslax 50mg/5.0ml.
• This product was first approved by the Japanese
  Ministry of Health, Labour and Welfare (MHLW) on
  July 31, 2007, under the name Eslax 1.
  However, the product was subsequently
  re-submitted using different brand names Eslax
  25mg/2.5ml and Eslax 50mg/5.0ml.

16
Key Therapeutic Areas

• Contraception World leader
• Hormone Therapy Pioneer in this field Eight
  decades.
• Fertility 75 years in this field
• Anesthesia Number one choice products
• Mental Health
• Cancer

17
Oral contraceptives

• Cerazette
• - Suitable for breast-feeding women.
• - For women sensitive to estrogen.
• Desogen/ Marvelon
• - One of the most successful oral
  contraceptives.
• - Monophasic combined low-dose (estrogen,
  progestogen).
• Gracial
• - For women who experience unacceptable
  irregular bleeds with other brands.
• - 22 day combiphasic (Estrogen drops and
  progesteron increases).
• Mercilon
• - Launched in 1988.
• - The first very low-dose oral contraceptive.
• Laurina
• - Low-dose.
• - For women with oily skin.

18

• Vaginal rings
• Nuvaring
• - Monthly vaginal ring.
• - Very low doses of hormones.
• - Rare irregular bleeding.

• Subdermal contraceptive implant
• Implanon
• - Result of 12 years of Research.
• - Inserted under the skin.
• - Lasts three years.

19
Hormone Therapy

• Andriol - Testosterone replacement therapy in
  aging men.
• Livial - Treatment of menopausal symptoms
• - Prevention of osteoporosis
• Ovestin - Treatment of symptoms caused by the
  atrophy of the lower urogenital tract following
  menopause
• Riselle - Implanted form of estrogen therapy
• - Single use implant device
• - Treatment of menopausal symptoms
• - Prevention of osteoporosis

20
Fertility

• Puregon/Follistim - Organons leading product
• - Contributes to the success of
  infertility treatments such as IVF
  (in vitro fertilization) and ICSI
  (intracytoplasmic sperm injection).
• - Ovulation induction.
• Orgalutran - Reduces IVF treatment from 4 weeks
  to 2 weeks
• - Reduced exposure to drugs.
• - Reduced physical and emotional burdens.
• Pregnyl - Injectable (since 1932)
• - Obtained from the urine of pregnant women
  (purified HCG)
• - Triggers ovulation.

21
Mental Health

• Tolvon First anti depressant launched in 1974.
  Tetracyclic.
• Remeron / Remeron SolTab
• First in class antidepressant dual action on
  noradrenergic and serotonergic systems.
• More than 17 million people treated with Remeron.
• Remeron SolTab dissolves on the tongue in less
  than 30 seconds.
• Currently conducting genomic research into manic
  depression and schizophrenia.

22
Anesthesia

• Pavulon
• - First neuromuscular blocking agent (NMBA),
  introduced in 1968.
• - Preferred in cardiac procedures.
• Orgaran
• - Unique non-heparin antithrombotic.
• - Injected subcutaneously or intravenously.
• - Suitable for children, pregnant women,
  patients with renal failure.
• Esmeron/Zemuron (USA/ Canada)
• - Neuromuscular blocking agent with fast onset
  action.
• - Approved for rapid use, emergency situations
  and for longer procedures.
• Norcuron
• - Neuromuscular blocking agent with superior
  cardiac safety profile.
• - On the market for more than 20 years.
• TOF-watch
• - Device which detects levels of muscle
  relaxation
• / neuromuscular transmission.

23
Cancer

• OncoTICE
• - Immunotherapeutic agent.
• - Treatment of superficial bladder cancer.
• - Similar preparation to many vaccines.
• - Six weekly treatments, followed by regular
  maintenance treatments for one year.

24
RD Trends

• - They have been focusing their RD efforts on
  neuroscience, immunology and biotech while
  continuing to maintain their core areas of
  anesthesia and reproductive medicine.
• - Organon strategically supplements its internal
  RD efforts by forging business partnerships.
• Fred Hassan, Schering-Ploughs Chairman and CEO
  said
• With Organon, we acquire a robust biologics
  manufacturing capability that is an excellent
  match for our earlier-stage biologics projects.
• " We expand into two important prescription
  pharmaceutical franchises, women's health and
  central nervous system (CNS). "These therapeutic
  areas add to our existing strengths in
  cardiovascular care, respiratory, immunology and
  oncology."

25
RD pipeline
26
Late Stage Products

• Asenapine
• - Psychopharmacologic agent being developed by
  Organon
• - Viewed as one of Organons brightest drug
  prospects, and a key reason why Schering-Plough
  agreed to pay 15.6 billion for the company.
• - Data from Phase III clinical trials were
  presented in October at the ECNP meeting.
• - Effective in treating acute manic episodes
  associated with bipolar I Disorder.
• - Minimal side effects in patients with
  Schizophrenia.

27
Info about the visit site

• Address 56 Livingston Avenue?
• Roseland, NJ 07068?
• Phone[phone]
• Fax[phone]
• Website www.organon-usa.com